Oct. 16, 2020 — Pfizer may not observe for emergency authorization of its coronavirus vaccine ahead of the 3rd week in November, the corporate’s leader government stated in a commentary posted to Pfizer’s site on Friday.

The reversal from the corporate’s earlier claims that it will observe for the approval in October is a blow to U.S. President Donald Trump, who again and again stated {that a} vaccine can be to be had ahead of Election Day on Nov. 3, The New York Times reported.

Even although Pfizer may have initial knowledge concerning the vaccine‘s effectiveness via the top of October, collecting protection and production knowledge would take till no less than the 3rd week of November, Dr. Albert Bourla stated within the commentary.

Pfizer’s announcement used to be welcomed via some scientists.

“This is just right, truly just right,” Dr. Eric Topol, a scientific trial skilled at Scripps Research in San Diego, instructed The Times. He used to be considered one of 60 public well being officers and different scientific professionals who despatched a letter to Pfizer urging it to not rush its vaccine, The Times reported.

Pfizer is considered one of 4 firms with a coronavirus vaccine in late-stage scientific trials within the United States. The others are Moderna, AstraZeneca and Johnson & Johnson. Pfizer has given probably the most positive timeline, whilst the opposite 3 have stated later this yr is much more likely.



WebMD News from HealthDay



Copyright © 2013-2020 HealthDay. All rights reserved.

LEAVE A REPLY

Please enter your comment!
Please enter your name here